Navigation Links
Discovery supports theory of Alzheimer's disease as form of diabetes
Date:9/26/2007

EVANSTON, Ill. --- Insulin, it turns out, may be as important for the mind as it is for the body. Research in the last few years has raised the possibility that Alzheimers memory loss could be due to a novel third form of diabetes.

Now scientists at Northwestern University have discovered why brain insulin signaling -- crucial for memory formation -- would stop working in Alzheimers disease. They have shown that a toxic protein found in the brains of individuals with Alzheimers removes insulin receptors from nerve cells, rendering those neurons insulin resistant. (The protein, known to attack memory-forming synapses, is called an ADDL for amyloid -derived diffusible ligand.)

With other research showing that levels of brain insulin and its related receptors are lower in individuals with Alzheimers disease, the Northwestern study sheds light on the emerging idea of Alzheimers being a type 3 diabetes.

The new findings, published online by the FASEB Journal, could help researchers determine which aspects of existing drugs now used to treat diabetic patients may protect neurons from ADDLs and improve insulin signaling in individuals with Alzheimers. (The FASEB Journal is a publication of the Federation of American Societies for Experimental Biology.)

In the brain, insulin and insulin receptors are vital to learning and memory. When insulin binds to a receptor at a synapse, it turns on a mechanism necessary for nerve cells to survive and memories to form. That Alzheimers disease may in part be caused by insulin resistance in the brain has scientists asking how that process gets initiated.

We found the binding of ADDLs to synapses somehow prevents insulin receptors from accumulating at the synapses where they are needed, said William L. Klein, professor of neurobiology and physiology in the Weinberg College of Arts and Sciences, who led the research team. Instead, they are piling up where they are made, in the cell body, near the nucleus. Insulin cannot reach receptors there. This finding is the first molecular evidence as to why nerve cells should become insulin resistant in Alzheimers disease.

ADDLS are small, soluble aggregated proteins. The clinical data strongly support a theory in which ADDLs accumulate at the beginning of Alzheimers disease and block memory function by a process predicted to be reversible.

In earlier research, Klein and colleagues found that ADDLs bind very specifically at synapses, initiating deterioration of synapse function and causing changes in synapse composition and shape. Now Klein and his team have shown that the molecules that make memories at synapses -- insulin receptors -- are being removed by ADDLs from the surface membrane of nerve cells.

We think this is a major factor in the memory deficiencies caused by ADDLs in Alzheimers brains, said Klein, a member of Northwesterns Cognitive Neurology and Alzheimer's Disease Center. Were dealing with a fundamental new connection between two fields, diabetes and Alzheimers disease, and the implication is for therapeutics. We want to find ways to make those insulin receptors themselves resistant to the impact of ADDLs. And that might not be so difficult.

Using mature cultures of hippocampal neurons, Klein and his team studied synapses that have been implicated in learning and memory mechanisms. The extremely differentiated neurons can be investigated at the molecular level. The researchers studied the synapses and their insulin receptors before and after ADDLs were introduced.

They discovered the toxic protein causes a rapid and significant loss of insulin receptors from the surface of neurons specifically on dendrites to which ADDLs are bound. ADDL binding clearly damages the trafficking of the insulin receptors, preventing them from getting to the synapses. The researchers measured the neuronal response to insulin and found that it was greatly inhibited by ADDLs.

In addition to finding that neurons with ADDL binding showed a virtual absence of insulin receptors on their dendrites, we also found that dendrites with an abundance of insulin receptors showed no ADDL binding, said co-author Fernanda G. De Felice, a visiting scientist from Federal University of Rio de Janeiro who is working in Kleins lab. These factors suggest that insulin resistance in the brains of those with Alzheimers is a response to ADDLs.

With proper research and development the drug arsenal for type 2 diabetes, in which individuals become insulin resistant, may be translated to Alzheimers treatment, said Klein. I think such drugs could supercede currently available Alzheimers drugs.


'/>"/>

Contact: Megan Fellman
fellman@northwestern.edu
847-491-3115
Northwestern University
Source:Eurekalert

Related medicine news :

1. OHSU Researchers Announce New Discovery
2. Discovery of bone gene
3. Latest discovery on Autism
4. Bacterial discovery may help CF patients
5. A new discovery about Acetaminophen
6. A new discovery about Acetaminophen
7. Resistant tumors could be treated with the discovery of a new molecule within cancer cells
8. Treatment for cholesterol-related illnesses likely with the discovery of receptor in mice
9. Ways to counter radiation effects with new molecule discovery
10. Canada stunned as mad cow discovery leads to beef ban
11. Mouth Infection better handled with new discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO ... year. Dyer started as the Chairman of the Management Committee when IFN was ... corporation including the recruitment of investor/owners and development of the business plan. He ...
(Date:2/23/2017)... ... 2017 , ... Thinksport, the most award-winning sunscreen on the ... Marin. For the second year in a row, cyclists will stay protected from ... thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts again ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial ... 74th Annual Meeting. KLS is a longtime supporter of the event. , "We ... and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... “Doping in Sport: How the Culture Might Change,” in conjunction with ... symposium will be held at Pepperdine University in Malibu, California. , Sir Philip ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)...  Xynomic Pharmaceuticals, Inc., an oncology drug research ... acquired exclusive worldwide rights to develop, manufacture and ... targeting hematological and solid tumors. To ... 2 clinical trials of Abexinostat in US, EU ... been completed, demonstrating that Abexinostat is clinically active ...
(Date:2/23/2017)... LG Innotek hat heute die weltweit erste ... das 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C ... und 280 nm und eignet sich damit für Sterilisationsaufgaben. Es ... zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung im ... ...
(Date:2/23/2017)... 2017 Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet ... der südwestlichen chinesischen Provinz Guizhou, 2017 mit dem Angebot von ... an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - ... ... ...
Breaking Medicine Technology: